<DOC>
	<DOCNO>NCT02955706</DOCNO>
	<brief_summary>clinical trial ass efficacy Acetyl-L-carnitine</brief_summary>
	<brief_title>Assessment Efficacy Acetyl-L-carnitine Patient With Alzheimer 's Disease</brief_title>
	<detailed_description>A multicenter , randomize , double-blind , placebo-controlled clinical trial ass efficacy Acetyl-L-carnitine patient Alzheimer 's disease</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>More 50 Years probable Alzheimer disease accord DSMIV NINCDSADRDA standard 12≤KMMSE ( screen ) ≤26 able perform examination Patient take donepezil ( 5mg 10mg/day ) 3 month able visit hospital caregiver possible probable definite vascular dementia accord NINDSAIREN standard CNS disease ( Cerebrovascular disease , Epilepsy etc ) cause dementia Illiteracy Patient take galantamine , memantine , rivastigmine within three month Patient take brain enhancer , thyroid hormone within 4 week Patient take Central nervous system stimulant , Antipsychotic agent , anticholinergic agent within 2 week screenig blood test : AST , ALT≥ 3 X upper limit normal range Hb≤8g/dL platelet &lt; 100,000/mm3 Serum creatinine ≥ 3 X upper limit normal range Abnormal result Vit.B12 , Syphilis serology , TSH Severe Depression , Schizophrenia , Alcoholism , Drug addiction Parkinson 's disease ( need drug therapy ) Angina , Myocardial infarction , ischemia within six month Head injury sense loss within six month Patient take IP within three month Hypersensitivity IP Sever Hearing problem Visual impairment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>